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Brief Clinical ReportsAbsidia corymbifera endocarditis: Survival after treatment
of disseminated mucormycosis with radical resection
of tricuspid valve and right ventricular free wallMichael E. Mitchell, MD,a Michael McManus, MD,d Julie Dietz, MD,d Bruce M. Camitta, MD,b
Sara Szabo, MD, PhD,c and Peter Havens, MD,b Milwaukee and Marshfield, WisDisseminated mucormycosis is a rare and almost univer-
sally fatal disorder.1,2 Successful treatment requires complete
surgical resection combined with antifungal chemotherapy,
but such resection may be impossible when cardiac tissues
are involved.3 There are few reports of successfully treated
mucormycosis in cardiac tissues and no reports of successfully
treated native valve endocarditis caused by mucormycosis or
zygomycosis.4-11 We describe the cure of disseminated mu-
cormycosis and native tricuspid valve endocarditis in a 6-
year-old child to demonstrate the possibility of a successful
outcome and emphasize the need for aggressive resection.FIGURE 1. Intraoperative photograph immediately before radical resection.CLINICAL SUMMARY
The patient was a 6-year-old previously healthy girl in
whom T-cell acute lymphoblastic leukemia was diagnosed.
She underwent four drug induction treatments lasting 28
days according to Children’s Oncology Group regimen
AALL0232 PC. This regimen included vincristine, predni-
sone, daunorubicin, and pegaspargase, plus intrathecal treat-
ment with cytarabine and methotrexate. The disease was in
complete remission at the end of induction, and she began
consolidation therapy that included cyclophosphamide, cy-
tarabine, mercaptopurine, vincristine, and pegaspargase,
plus intrathecal methotrexate. On day 40 of consolidation
therapy, the patient was readmitted for fever to 104.3F
(40C), neutropenia, and tachycardia. On hospital day 3,
central venous line blood culture showed growth of filamen-
tous fungus (later identified as Absidia corymbifera). Am-
photericin B (Ambisome, 5 mg/kg per dose) was started,
and the central venous line was removed. Computed tomo-
graphic scan of the neck, chest, abdomen, and pelvis showed
bilateral nodular pulmonary densities and a right ventricular
mass. Echocardiogram defined a 2 3 1.5-cm right ventricu-
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The Journal of Thoracic and CaThe patient was taken to the operating room on an emer-
gency basis. Surgery consisted of de´bridement of a large (3
3 3 cm) fungus ball inferior to the posterior leaflet of the tri-
cuspid valve and involving the free wall of the right ventri-
cle. The resection was not complete. The posterior leaflet of
the tricuspid valve and subvalvular apparatus were inti-
mately involved with a small amount of grossly detectable
fungus. Lung lesions were not resected. Amphotericin B
was increased to 10 mg/kg per day. The patient recovered
rapidly, with no tricuspid insufficiency, and was discharged
to home on postoperative day 11.
On postoperative day 25, the patient returned to the emer-
gency department with shortness of breath and tachycardia.
Spiral chest computed tomography revealed progression of
disease,with growth of themass in the right ventricle and em-
bolization into the right pulmonary artery. She was taken to
the operating room on an urgent basis for radical resection
of all involved cardiac tissues (Figure 1). This surgery in-
cludedwide resection of the right ventricular free wall, resec-
tion of the posterior leaflet of the tricuspid valve and
subvalvular apparatus, and resection of two dominant left-
sided lung nodules. All margins were grossly free of fungus.
The right ventricle was reconstructed primarily, and the tri-
cuspid valve was bicuspidized with resection of the posteriorrdiovascular Surgery c Volume 139, Number 4 e71
FIGURE 2. Histology. A, Numerous fungal hyphae infiltrating the myo-
cardium, with necrosis (hematoxylin and eosin stain). B, Fungal hyphae
morphologically consistant with zygomycetes (Giemsa stain).
Brief Clinical Reportsleaflet and subvalvular apparatus, followed by an extensive
DeVega annuloplasty. Areas of abscess in the left upper
lobe and lingula were also removed. Postoperative transeso-
phageal echocardiography confirmed mild to moderate tri-
cuspid regurgitation and mild tricuspid stenosis. The
patient was extubated in the operating room and transferred
to the intensive care unit with a regimen of dopamine andmil-
rinone, as well as amphotericin B (10 mg/kg per day). Posa-
conazole (200 mg orally twice daily) was added (under
a compassionate use protocol before approval by the Food
and Drug Administration). Pathologic examination of the
myocardial tissue demonstrated extensively infiltrating fun-
gal hyphae consistent with mucormycosis (zygomycosis),
with myocardial necrosis and limited host response (Figure
2). The pulmonary tissue showed only an inflammatory and
reparative host reaction. The patient was discharged from
the hospital on postoperative day 11 with a regimen of am-
photericin B and posaconazole.
Latest echocardiogram at 16months of follow-up revealed
moderate to severe tricuspid regurgitation with good right
ventricular function.Nowat 21months after resection, full re-
mission of acute lymphoblastic leukemia continues, and the
patient is in New York Heart Association functional class I.e72 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
Mucormycosis endocarditis is a rare disorder, typically in-
volving infection of prosthetic valves after cardiac surgery in
immunocompromised hosts.5,6,8,9Mucormycosis endocardi-
tis involving a native valve is extremely uncommon.4,10 The
successful outcome in our case after radical resection of the
primary infectious focus, despite disseminated disease with
rapidly positive blood cultures, illustrates both the impor-
tance of aggressive therapy when possible and the possibility
of resolution once the initial focus of infection has been re-
moved. Although the principle of obtaining clear margins
in surgical resections of nonessential tissue infected with
fungi of the Mucorales order is widely accepted, aggressive
resection of essential tissue, such as cardiac tissue, in the
face of disseminated disease is not a common practice. In
this case radical resection, including bicuspidization of the
tricuspid valve, was well tolerated and resulted in clearing
of the systemic fungemia, allowing immunosuppressive
chemotherapy to be resumed.
Antifungal therapy for mucormycosis with liposomal am-
photericin B (Ambisome or Abelcet) may be more effective
than therapy with amphotericin B deoxycholate.1 Posacona-
zole may be effective in patients with refractory disease or
intolerance of Ambisome therapy.12
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